545 related articles for article (PubMed ID: 17032149)
21. Body composition and bone metabolism in young Gaucher disease type I patients treated with imiglucerase.
Parisi MS; Mastaglia SR; Bagur A; Goldstein G; Zeni SN; Oliveri B
Eur J Med Res; 2008 Jan; 13(1):31-8. PubMed ID: 18226995
[TBL] [Abstract][Full Text] [Related]
22. Velaglucerase alfa enzyme replacement therapy compared with imiglucerase in patients with Gaucher disease.
Ben Turkia H; Gonzalez DE; Barton NW; Zimran A; Kabra M; Lukina EA; Giraldo P; Kisinovsky I; Bavdekar A; Ben Dridi MF; Gupta N; Kishnani PS; Sureshkumar EK; Wang N; Crombez E; Bhirangi K; Mehta A
Am J Hematol; 2013 Mar; 88(3):179-84. PubMed ID: 23400823
[TBL] [Abstract][Full Text] [Related]
23. Timing of initiation of enzyme replacement therapy after diagnosis of type 1 Gaucher disease: effect on incidence of avascular necrosis.
Mistry PK; Deegan P; Vellodi A; Cole JA; Yeh M; Weinreb NJ
Br J Haematol; 2009 Nov; 147(4):561-70. PubMed ID: 19732054
[TBL] [Abstract][Full Text] [Related]
24. Impact of imiglucerase on the serum glycosylated-ferritin level in Gaucher disease.
Stirnemann J; Boutten A; Vincent C; Mekinian A; Heraoui D; Fantin B; Fain O; Mentré F; Belmatoug N
Blood Cells Mol Dis; 2011 Jan; 46(1):34-8. PubMed ID: 21084203
[TBL] [Abstract][Full Text] [Related]
25. Enzyme replacement therapy with imiglucerase in a Taiwanese child with type 1 Gaucher disease.
Lin HY; Lin SP; Chuang CK; Wraith JE
J Chin Med Assoc; 2006 May; 69(5):228-32. PubMed ID: 16835986
[TBL] [Abstract][Full Text] [Related]
26. Characteristics of type I Gaucher disease associated with persistent thrombocytopenia after treatment with imiglucerase for 4-5 years.
Hollak CE; Belmatoug N; Cole JA; Vom Dahl S; Deegan PB; Goldblatt J; Rosenbloom B; van Dussen L; Tylki-Szymańska A; Weinreb NJ; Zimran A; Cappellini MD
Br J Haematol; 2012 Aug; 158(4):528-38. PubMed ID: 22640238
[TBL] [Abstract][Full Text] [Related]
27. Safety and efficacy results of switch from imiglucerase to velaglucerase alfa treatment in patients with type 1 Gaucher disease.
Elstein D; Mehta A; Hughes DA; Giraldo P; Charrow J; Smith L; Shankar SP; Hangartner TN; Kunes Y; Wang N; Crombez E; Zimran A
Am J Hematol; 2015 Jul; 90(7):592-7. PubMed ID: 25776130
[TBL] [Abstract][Full Text] [Related]
28. Long-term clinical outcomes in type 1 Gaucher disease following 10 years of imiglucerase treatment.
Weinreb NJ; Goldblatt J; Villalobos J; Charrow J; Cole JA; Kerstenetzky M; vom Dahl S; Hollak C
J Inherit Metab Dis; 2013 May; 36(3):543-53. PubMed ID: 22976765
[TBL] [Abstract][Full Text] [Related]
29. Long-term velaglucerase alfa treatment in children with Gaucher disease type 1 naïve to enzyme replacement therapy or previously treated with imiglucerase.
Smith L; Rhead W; Charrow J; Shankar SP; Bavdekar A; Longo N; Mardach R; Harmatz P; Hangartner T; Lee HM; Crombez E; Pastores GM
Mol Genet Metab; 2016 Feb; 117(2):164-71. PubMed ID: 26043810
[TBL] [Abstract][Full Text] [Related]
30. The effect of enzyme replacement therapy on bone crisis and bone pain in patients with type 1 Gaucher disease.
Charrow J; Dulisse B; Grabowski GA; Weinreb NJ
Clin Genet; 2007 Mar; 71(3):205-11. PubMed ID: 17309642
[TBL] [Abstract][Full Text] [Related]
31. A phase 2 multi-center, open-label, switch-over trial to evaluate the safety and efficacy of Abcertin® in patients with type 1 Gaucher disease.
Choi JH; Lee BH; Ko JM; Sohn YB; Lee JS; Kim GH; Heo SH; Park JY; Kim YM; Kim JH; Yoo HW
J Korean Med Sci; 2015 Apr; 30(4):378-84. PubMed ID: 25829804
[TBL] [Abstract][Full Text] [Related]
32. Improvement of bone disease by imiglucerase (Cerezyme) therapy in patients with skeletal manifestations of type 1 Gaucher disease: results of a 48-month longitudinal cohort study.
Sims KB; Pastores GM; Weinreb NJ; Barranger J; Rosenbloom BE; Packman S; Kaplan P; Mankin H; Xavier R; Angell J; Fitzpatrick MA; Rosenthal D
Clin Genet; 2008 May; 73(5):430-40. PubMed ID: 18312448
[TBL] [Abstract][Full Text] [Related]
33. Neurologic improvement in a type 3 Gaucher disease patient treated with imiglucerase/miglustat combination.
Capablo JL; Franco R; de Cabezón AS; Alfonso P; Pocovi M; Giraldo P
Epilepsia; 2007 Jul; 48(7):1406-8. PubMed ID: 17433057
[TBL] [Abstract][Full Text] [Related]
34. Bone density changes with enzyme therapy for Gaucher disease.
Lebel E; Dweck A; Foldes AJ; Golowa Y; Itzchaki M; Zimran A; Elstein D
J Bone Miner Metab; 2004; 22(6):597-601. PubMed ID: 15490271
[TBL] [Abstract][Full Text] [Related]
35. Imiglucerase (Cerezyme) improves quality of life in patients with skeletal manifestations of Gaucher disease.
Weinreb N; Barranger J; Packman S; Prakash-Cheng A; Rosenbloom B; Sims K; Angell J; Skrinar A; Pastores GM
Clin Genet; 2007 Jun; 71(6):576-88. PubMed ID: 17539908
[TBL] [Abstract][Full Text] [Related]
36. Long-term bone outcomes in Italian patients with Gaucher disease type 1 or type 3 treated with imiglucerase: A sub-study from the International Collaborative Gaucher Group (ICGG) Gaucher Registry.
Cappellini MD; Carubbi F; Di Rocco M; Giona F; Giuffrida G
Blood Cells Mol Dis; 2023 Jan; 98():102705. PubMed ID: 36327675
[TBL] [Abstract][Full Text] [Related]
37. Changes of bone metabolism in seven patients with Gaucher disease treated consecutively with imiglucerase and miglustat.
Mikosch P; Reed M; Baker R; Holloway B; Berger L; Mehta AB; Hughes DA
Calcif Tissue Int; 2008 Jul; 83(1):43-54. PubMed ID: 18553043
[TBL] [Abstract][Full Text] [Related]
38. Impact on bone microarchitecture and failure load in a patient with type I Gaucher disease who switched from Imiglucerase to Eliglustat.
Sidhu K; Boyd SK; Khan A
Mol Genet Metab Rep; 2020 Sep; 24():100606. PubMed ID: 32509532
[TBL] [Abstract][Full Text] [Related]
39. Taliglucerase alfa: safety and efficacy across 6 clinical studies in adults and children with Gaucher disease.
Zimran A; Wajnrajch M; Hernandez B; Pastores GM
Orphanet J Rare Dis; 2018 Feb; 13(1):36. PubMed ID: 29471850
[TBL] [Abstract][Full Text] [Related]
40. A randomized trial comparing the efficacy and safety of imiglucerase (Cerezyme) infusions every 4 weeks versus every 2 weeks in the maintenance therapy of adult patients with Gaucher disease type 1.
Kishnani PS; DiRocco M; Kaplan P; Mehta A; Pastores GM; Smith SE; Puga AC; Lemay RM; Weinreb NJ
Mol Genet Metab; 2009 Apr; 96(4):164-70. PubMed ID: 19195916
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
